Stage III nonsmall cell lung cancer (NSCLC) comprises about one-third of NSCLC patients
and is very heterogeneous with varying and mostly poor prognosis. It is also called “…

Purpose The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment
of advanced NSCLC, leading to a string of approvals in recent years. Herein, a narrative …

Introduction Afatinib is an effective first-line treatment in patients with epidermal growth factor
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in …

Biological markers are urgently needed to improve the early detection, diagnosis and
treatment of lung tumours. Over the past several years various promising biomarkers have …

The reason for weight loss at high altitudes is largely unknown. To date, studies have been
unable to differentiate between weight loss due to hypobaric hypoxia and that related to …

Immune microenvironment plays a critical role in lung cancer control versus progression
and metastasis. In this investigation, we explored the effect of tumor-infiltrating lymphocyte …

Objectives: Myeloid-derived suppressor cells (MDSCs) have been described as suppressors
of T-cell functions in many tumor models. However, MDSC in HIV-1 infection have not been …

Abstract Treatment with single agent immune checkpoint inhibitors (ICIs) has tremendously
changed second line therapy in NSCLC. However, there are still no reliable biomarkers …

Background Knowledge of differences in the cellular physiology of malignant and non-malignant
cells is a prerequisite for the development of cancer treatments that effectively kill …

Introduction The NICOLAS study is the first completed single-arm phase II trial in stage III
NSCLC evaluating hierarchically first the safety and then the efficacy of adding nivolumab …